Latest Regulatory News

Strickland Metals has completed the distribution of Gateway Mining shares to its shareholders following the sale of its Yandal Project, marking a significant step in its corporate restructuring.

Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.

Alligator Energy has secured final regulatory approval to begin its in-situ Field Recovery Trial at the Samphire Uranium Project, advancing the development of its recently upgraded Blackbush Deposit resource.

Regal Partners Limited has announced a fully franked ordinary dividend of AUD 0.06 per share for the first half of FY25, alongside a dividend reinvestment plan open to Australian and New Zealand shareholders.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.

Power Minerals Limited reports exceptional high-grade rare earth and niobium intersections from shallow drilling at its Santa Anna Project in Brazil, reinforcing its potential for a significant mineral resource.

Santos Limited reports a 31% drop in net profit for H1 2025 despite increased sales volumes and progress on key projects, while receiving a non-binding acquisition proposal from an Abu Dhabi-led consortium.

Diatreme Resources has achieved a significant regulatory milestone with Project Status granted across its silica sand tenements in Far North Queensland, alongside critical tenure renewals that preserve its strategic landholdings. This development strengthens its pathway toward long-term production of low-iron, high-purity silica sand.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

BetMakers Technology Group is poised to release its FY25 financial results on August 28, accompanied by a detailed investor webinar featuring key executives. The event promises to shed light on the company’s recent performance and strategic direction in racing technology solutions.

Michael Hill International reported a steady FY25 with revenue holding firm at $643.7 million and a return to profitability despite ongoing retail challenges. The year saw strategic store closures, digital sales growth, and leadership changes, setting the stage for a reset under new CEO Jonathan Waecker.